Inventiva (IVA) Competitors $5.31 -0.30 (-5.35%) Closing price 04:00 PM EasternExtended Trading$5.37 +0.06 (+1.13%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. IRON, BEAM, CNTA, BLTE, AGIO, HRMY, ANIP, ARQT, DYN, and RXRXShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Disc Medicine (IRON), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Belite Bio (BLTE), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), ANI Pharmaceuticals (ANIP), Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Its Competitors Disc Medicine Beam Therapeutics Centessa Pharmaceuticals Belite Bio Agios Pharmaceuticals Harmony Biosciences ANI Pharmaceuticals Arcutis Biotherapeutics Dyne Therapeutics Recursion Pharmaceuticals Inventiva (NASDAQ:IVA) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation. Do analysts prefer IVA or IRON? Inventiva presently has a consensus price target of $14.83, indicating a potential upside of 179.35%. Disc Medicine has a consensus price target of $98.30, indicating a potential upside of 64.11%. Given Inventiva's higher possible upside, equities analysts clearly believe Inventiva is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is IVA or IRON more profitable? Inventiva's return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Disc Medicine N/A -26.60%-24.58% Which has more risk & volatility, IVA or IRON? Inventiva has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Does the media refer more to IVA or IRON? In the previous week, Disc Medicine had 4 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Disc Medicine and 4 mentions for Inventiva. Disc Medicine's average media sentiment score of 1.55 beat Inventiva's score of 0.80 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders believe in IVA or IRON? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 3.6% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, IVA or IRON? Disc Medicine has lower revenue, but higher earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M51.05-$199.34MN/AN/ADisc MedicineN/AN/A-$109.36M-$4.47-13.40 SummaryDisc Medicine beats Inventiva on 8 of the 13 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$507.96M$3.11B$5.75B$10.28BDividend YieldN/A2.32%5.72%4.60%P/E RatioN/A21.3674.9926.41Price / Sales51.05240.89456.1088.49Price / CashN/A44.4425.8129.91Price / Book-4.399.6413.256.28Net Income-$199.34M-$53.20M$3.29B$270.38M7 Day Performance-1.12%0.41%0.46%2.69%1 Month Performance21.79%4.23%4.59%5.98%1 Year Performance137.05%9.41%73.41%25.93% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva2.9866 of 5 stars$5.31-5.3%$14.83+179.3%+150.4%$507.96M$9.95M0.00100Short Interest ↑IRONDisc Medicine3.2356 of 5 stars$61.91+1.9%$98.30+58.8%+25.2%$2.11BN/A-13.8530Positive NewsHigh Trading VolumeBEAMBeam Therapeutics3.1797 of 5 stars$19.94-4.5%$48.45+143.0%-21.7%$2.11B$63.52M-4.43510Analyst DowngradeCNTACentessa Pharmaceuticals3.1393 of 5 stars$18.03+14.6%$31.45+74.5%+28.4%$2.11B$6.85M-10.07200Positive NewsGap UpHigh Trading VolumeBLTEBelite Bio2.5809 of 5 stars$67.51+2.7%$96.67+43.2%+42.3%$2.09BN/A-43.5510News CoverageAnalyst ForecastAGIOAgios Pharmaceuticals4.3185 of 5 stars$36.41+1.1%$56.00+53.8%-21.2%$2.09B$40.88M3.31390HRMYHarmony Biosciences4.6027 of 5 stars$35.83-0.4%$51.00+42.3%-16.8%$2.07B$714.73M11.56200Positive NewsHigh Trading VolumeANIPANI Pharmaceuticals3.9363 of 5 stars$95.20-0.2%$88.25-7.3%+67.0%$2.07B$747.40M-123.63600ARQTArcutis Biotherapeutics2.4501 of 5 stars$17.33+1.0%$19.80+14.3%+62.2%$2.06B$196.54M-23.11150DYNDyne Therapeutics3.9341 of 5 stars$13.30-6.5%$34.07+156.1%-61.4%$2.02BN/A-3.45100Positive NewsRXRXRecursion Pharmaceuticals2.2986 of 5 stars$4.62+0.2%$7.25+56.9%-26.5%$2.00B$58.84M-2.60400Positive News Related Companies and Tools Related Companies IRON Competitors BEAM Competitors CNTA Competitors BLTE Competitors AGIO Competitors HRMY Competitors ANIP Competitors ARQT Competitors DYN Competitors RXRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVA Stock Alerts